TAC与AT方案新辅助化疗治疗局部晚期乳腺癌疗效分析

Efficacy of neoadjuvant chemotherapy regimen of TAC and AT for locally advanced breast cancer

目的:观察多西他赛、吡柔比星联合环磷酰胺方案(TAC)与多西他赛联合吡柔比星方案(AT)新辅助化疗治疗局部晚期乳腺癌近期疗效和毒副反应。方法:回顾性分析72例局部晚期乳腺癌新辅助化疗患者资料,TAC组(38例)为观察组,AT组(34例)为对照组,每周期化疗前行疗效评估及毒副反应分析,第4周期化疗结束后总体评价疗效。结果:观察组治疗局部晚期乳腺癌总有效率为89.47%,对照组为70.59%,观察组优于对照组,差异有统计学意义(P<0.05);化疗毒副反应严重程度观察组较对照组重,两组之间差异无统计学意义(P>0.05)。结论:TAC与AT方案新辅助化疗治疗局部晚期乳腺癌均有较好疗效,TAC方案优于AT方案。

Objective： To explore the immediate effect and adverse reaction of different chemotherapy regimens： Docetaxel ＋ THP ＋ cyelophosphamide and docetaxel ＋ THP in the treatment of locally advanced breast cancer. Meth- ods：To analyze retrospectively the locally advanced breast cancer information of 72 cases in type Ⅱ b - Ⅲc period. All patients were randomly divided into two groups. The observation group 38 cases applied the treatment of docetaxel ＋ THP ＋ cyclophosphamide. The control group 34 cases applied the treatment of docetaxel ＋ THP. The efficacy and adverse reaction were evaluated and analyzed every course of treatment, the total efficiency was evaluated after four course of treatment. Results ： The total efficiency of the observation group in treatment of locally advanced breast canc- er was 89.47% , and 70.59% in control group （P 〈 0.05 ）. Adverse reaction of chemotherapy had high incidence, but there was no significant difference （P 〉 0.05 ）. Conclusion ：The neoadjuvant chemotherapy of TAC and AT is both ef- fective in the treatment of locally advanced breast cancer, and TAC scheme superior to AT plan.